Reduction in MPS1 levels or activity in such tumours can result in loss of cell viability (Daniel et al, 2011; Slee et al, 2014), or in increased sensitivity to low doses of microtubule-polymerising agents such as docetaxel (Tannous et al, 2013; Maia et al, 2015). Here, TTK is linked to neoplasm.